SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other Events
Item 8.01 Other Events.
of Nevada in and for Clark County entered an Order Preliminarily
Approving Settlement and Providing for Notice in the shareholder
derivative actions Kakadia v. Shrotriya, No. A-13-680643-B and
Besner v. Shrotriya, No. A-13-682668-C, pending in the Eighth
Judicial District Court of the State of Nevada, consolidated with
In re Spectrum Pharmaceuticals, Inc., Derivative Shareholder
Litigation, Case No. 13-cv-00624-JAD-CWH, pending in the U.S.
District Court for the District of Nevada. A final settlement
hearing is currently scheduled for July 20, 2017, at 9 a.m., at
the Eighth Judicial District Court of the State of Nevada in and
for Clark County, 200 Lewis Avenue, Las Vegas, NV 89101, to
determine whether the terms and conditions of the settlement
provided for in the Stipulation of Settlement, dated April 11,
2017 (the Stipulation), are adequate, fair and reasonable and in
the best interests of the Company and its shareholders. to the
Stipulation, the Company agreed to implement certain operational
and corporate governance measures and pay certain attorneys fees
and expenses to plaintiffs counsel. The Summary Notice of
Proposed Settlement is attached to this Current Report on Form
8-K as Exhibit 99.1, and is incorporated into this Item 8.01 by
reference. The Stipulation and the Notice of Proposed Settlement
and Settlement Hearing are available on the Companys corporate
website at http://investor.sppirx.com until July 6, 2017. The
contents of the Companys corporate website shall not be deemed to
be incorporated by reference into this Current Report on Form
8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Summary Notice of Proposed Settlement
|
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.
